BridgeBio Oncology Therapeutics (NASDAQ:BBOT) Sees Large Volume Increase - Still a Buy?

Key Points

• Shares last traded at $8.9550 (previous close $8.40) on volume of 243,081 shares, a 14% decline from the prior session; the stock has a 50‑day SMA of $9.86 and a market cap of $723.39 million.
• Analyst sentiment is mixed-to-positive with three Buys and one Sell, giving an average rating of "Moderate Buy" and an average price target of $26, while HC Wainwright recently raised its target to $29.
• Institutional investors own 54.89% of the company, with notable fourth‑quarter stake increases from Armistice Capital (to 1,000,000 shares), Laurion Capital and Paradigm Biocapital, and new positions from Catalio and Goldman Sachs.

BridgeBio Oncology Therapeutics, Inc (NASDAQ:BBOT - Get Free Report) shares saw unusually-strong trading volume on Monday . Approximately 243,081 shares traded hands during trading, a decline of 14% from the previous session's volume of 282,410 shares.The stock last traded at $8.9550 and had previously closed at $8.40.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on BBOT shares. Raymond James Financial raised BridgeBio Oncology Therapeutics to a "moderate buy" rating in a research report on Friday, January 9th. Weiss Ratings began coverage on BridgeBio Oncology Therapeutics in a research report on Wednesday, January 14th. They set a "sell (d+)" rating for the company. Stifel Nicolaus began coverage on BridgeBio Oncology Therapeutics in a research report on Tuesday, February 10th. They set a "buy" rating and a $23.00 price target for the company. Finally, HC Wainwright lifted their price target on BridgeBio Oncology Therapeutics from $27.00 to $29.00 and gave the stock a "buy" rating in a research report on Friday, March 6th. Three investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, BridgeBio Oncology Therapeutics currently has an average rating of "Moderate Buy" and an average price target of $26.00.

BridgeBio Oncology Therapeutics Stock Performance

The company has a 50 day simple moving average of $9.86. The firm has a market cap of $723.39 million, a PE ratio of -5.95 and a beta of 0.51.

Hedge Funds Weigh In On BridgeBio Oncology Therapeutics

A number of institutional investors have recently modified their holdings of BBOT. Armistice Capital LLC boosted its stake in shares of BridgeBio Oncology Therapeutics by 142.7% in the fourth quarter. Armistice Capital LLC now owns 1,000,000 shares of the company's stock worth $12,520,000 after buying an additional 588,000 shares during the last quarter. Laurion Capital Management LP raised its position in BridgeBio Oncology Therapeutics by 40.1% during the fourth quarter. Laurion Capital Management LP now owns 1,464,938 shares of the company's stock valued at $18,341,000 after acquiring an additional 419,138 shares in the last quarter. Catalio Capital Management LP acquired a new position in BridgeBio Oncology Therapeutics in the fourth quarter valued at approximately $5,142,000. Paradigm Biocapital Advisors LP boosted its position in BridgeBio Oncology Therapeutics by 21.2% in the 4th quarter. Paradigm Biocapital Advisors LP now owns 2,261,749 shares of the company's stock worth $28,317,000 after purchasing an additional 395,608 shares in the last quarter. Finally, Goldman Sachs Group Inc. purchased a new stake in BridgeBio Oncology Therapeutics in the 4th quarter worth approximately $1,185,000. Hedge funds and other institutional investors own 54.89% of the company's stock.

BridgeBio Oncology Therapeutics Company Profile

BridgeBio Oncology Therapeutics NASDAQ: BBOT is a publicly traded biotechnology company focused on discovering and developing therapies for cancer. The company concentrates on translating scientific insights into clinical-stage programs aimed at addressing oncology indications with unmet medical need.

BridgeBio Oncology’s activities center on research and development of investigational therapeutics, advancing drug candidates through preclinical studies and clinical trials. Its work typically involves in-house discovery efforts and collaborations with academic and industry partners to identify targets, optimize compounds, and generate the clinical data needed to support regulatory development.

Public information about BridgeBio Oncology Therapeutics’ specific programs, geographic operations and leadership is limited in the sources available here.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.